Basilea Pharmaceutica

Last updated
Basilea Pharmaceutica AG, Allschwil
Company type Public
SIX:  BSLN
Industry Pharmaceutical industry
Founded2000
Headquarters Allschwil, Switzerland
Key people
David Veitch (Chief Executive Officer) [1]
Domenico Scala (Chairman of the Board] [2]
Products Isavuconazole, Ceftobiprole
Revenue CHF 157.6 million (2023) [3]
Number of employees
147 (2023) [3]
Website www.basilea.com

Basilea Pharmaceutica is a biopharmaceutical company based in Allschwil near Basel, Switzerland. [4] Basilea was spun off from F. Hoffmann-La Roche in 2000 and has been listed as an independent company on the Swiss stock exchange since March 2004. [5] The company's subsidiary is Basilea Pharmaceutica International AG, Allschwil, which is also based in Allschwil, Switzerland, and in which the company's operating activities are bundled. [6]

Contents

History

Basilea Pharmaceutica was founded in 2000 as a corporate spin-off of the pharmaceutical company Roche. [5]

In 2002, Chinese subsidiary Basilea Pharmaceutica China Ltd. (BPC) was founded and was located in the Haimen Economic and Technological Development Zone in the city of Nantong in the Chinese province of Jiangsu, north of Shanghai. [7]

With the listing on the Swiss stock exchange in March 2004 at a price of CHF 98 per share, Basilea realised gross proceeds of more than CHF 200 million. [8]

In 2012, Basilea sold the worldwide rights to Toctino, a dermatology drug developed by Basilea that was approved and marketed in various European countries in 2008, to Stiefel Labs, a subsidiary of the British pharmaceutical company GlaxoSmithKline, for CHF 216 million. [9]

At the beginning of 2013, Basilea received orphan drug status in the USA for the antifungal drug Isavuconazole for the treatment of invasive fungal infections, which at the time, analysts estimated to be worth up to CHF 150 million per year. [10] [11] Isavuconazole was developed in phase III in conjunction with pharmaceutical company Astellas Pharma. [12] In March 2015, Isavuconazole was approved in the US, followed by the entire EU in October of the same year. [13] [14] In the following years, the drug was also approved in Japan, several Eurasian countries, Australia and China. [15]

In October 2013, Basilea received marketing authorisation in twelve European countries, including Germany, for the distribution of the broad-spectrum antibiotic Ceftobiprole for the treatment of bacterial lung infections; [16] [17] in the following two years, the drug was gradually approved in other European countries and non-EU countries. [18] [19] Ceftobiprole has been approved in 32 countries and has been marketed in 21 countries since the end of 2023. [19] [20]

In 2020, Basilea sold the group headquarters in Basel to the pension fund of the Swiss bank UBS by way of a sale-leaseback and moved to its new headquarters in Allschwil in mid-2022. [21] [22] The gross proceeds from the sale amounted to around CHF 19 million before fees and transaction costs. [22] In 2021, Basilea Pharmaceutica China Ltd. was sold to the US company PHT International. [23] Basilea was previously active in oncological research, but withdrew from it at the beginning of 2022 and has since been focusing purely on anti-infectives. [15] [24] In 2023, Basilea acquired the rights to the antifungal drug Fosmanogepix from Pfizer. [25]

By the end of 2023, Isavuconazole was commercialised in more than 70 countries, including the United States, most EU countries, China and Japan. Isavuconazole's total global sales in the twelve-month period between October 2022 and September 2023 amounted to CHF 406 million. This corresponds to growth of 22 per cent compared to the previous year. [26]

In early April 2024, the US Food and Drug Administration (FDA) approved Ceftobiprole for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia) and for adult patients with right-sided infective endocarditis. In addition, the FDA approved Ceftobiprole for the treatment of acute bacterial skin and skin structure infections in adult patients and in adult and pediatric patients aged three months to less than 18 years with community-acquired bacterial pneumonia (CAPB). [27]

Corporate structure

In the financial year 2023, Basilea Pharmaceutica AG, Allschwil generated company sales of CHF 157.6 million and employed 147 people. [3] Since the 2022 financial year, Basilea has consistently been generating operating and net profits. [28] [29]

In addition to its headquarters in Allschwil, Switzerland, [4] Basilea is represented by subsidiaries in the UK and Germany. [30]

Basilea cooperates with licence and distribution partners in over 100 countries. [31]

Products

The company's research and development activities are focused on drugs for the treatment of severe, resistant bacterial infections and life-threatening, invasive fungal diseases. [11] [32] [33]

Basilea's products are aimed at diseases that have so far been insufficiently treatable. [34] The company markets the following products exclusively through licence and distribution partners: [15]

Ceftobiprole (trade name Zevtera/Mabelio) is a broad-spectrum antibiotic administered intravenously for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) in adults. It has an active effect against the bacterium Staphylococcus aureus (MRSA), including methicillin-resistant strains, and against penicillin-resistant Streptococcus pneumoniae (PRSP) bacteria, as well as against gram-negative pathogens such as Enterobacteriaceae. [17] [35] [36]

Isavuconazole (trade name Cresemba) is an intravenous and oral antifungal agent for the treatment of patients with invasive aspergillosis and invasive mucormycosis. [37]

While Astellas is responsible for the commercialisation of Cresemba in the USA, [38] the pharmaceutical group Pfizer covers the commercialisation in most of Europe [39] and also distributes Cresemba in China and the Asia–Pacific (APAC) area. [40] Basilea's distribution partner in the MENA region is Hikma Pharmaceuticals LLC; [41] Knight Therapeutics Inc. commercialises the antifungal Cresemba in South America. [42]

Related Research Articles

<span class="mw-page-title-main">Ceftobiprole</span> Chemical compound

Ceftobiprole, sold under the brand name Zevtera among others, is a fifth-generation cephalosporin antibacterial used for the treatment of hospital-acquired pneumonia and community-acquired pneumonia. It is marketed by Basilea Pharmaceutica under the brand names Zevtera and Mabelio. Like other cephalosporins, ceftobiprole exerts its antibacterial activity by binding to important penicillin-binding proteins and inhibiting their transpeptidase activity which is essential for the synthesis of bacterial cell walls. Ceftobiprole has high affinity for penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus strains and retains its activity against strains that express divergent mecA gene homologues. Ceftobiprole also binds to penicillin-binding protein 2b in Streptococcus pneumoniae (penicillin-intermediate), to penicillin-binding protein 2x in Streptococcus pneumoniae (penicillin-resistant), and to penicillin-binding protein 5 in Enterococcus faecalis.

<span class="mw-page-title-main">Implenia</span> Swiss construction services company

Implenia is a Swiss real estate and construction services company with activities in development and civil engineering in Switzerland and Germany. Implenia is also active in tunneling and related infrastructure construction in Austria, France, Sweden, Norway and Italy. The Group was formed at the beginning of 2006 from the merger of Basel-based Batigroup Holding AG with Geneva-based Zschokke Holding SA. The headquarters are located in Glattpark (Opfikon) in the canton of Zurich. Implenia is one of the 500 largest companies in Switzerland.

<span class="mw-page-title-main">Isavuconazonium</span> Chemical compound

Isavuconazonium, sold under the brand name Cresemba, is a systemic antifungal medication of the triazole class which is used to treat invasive aspergillosis and mucormycosis. It is used as the sulfate. It is taken by mouth or given via injection into a vein.

WORLD.MINDS is a non-profit foundation set up in June 2008 by Rolf Dobelli, with the goal of creating "a bridge between the science, business and cultural communities".

Think Tools AG was a Swiss IT company that rose and fell with the dot-com bubble in Europe. The company was founded by the philosopher Albrecht von Müller as a consultancy company in 1993.

Debiopharm is a privately-held Swiss biopharmaceutical company mainly active in development and clinical testing of drug candidates. It was founded in 1979 by Rolland-Yves Mauvernay.

<span class="mw-page-title-main">Alpiq</span>

Alpiq is an internationally active energy group headquartered in Lausanne, Switzerland. The company was established in 2009 after the merger of Atel Holding AG and EOS S.A..

Helvetia is an international insurance group that exists since 1858. The group of companies has been organised in a holding structure since 1996. The head office of Helvetia Group is located in St. Gallen, Switzerland.

Digitec Galaxus AG is the biggest online retailer in Switzerland. The company is 70% owned by Migros and operates the Digitec and Galaxus online stores in Switzerland and neighboring EU countries. Galaxus is an online department store with a wide range of products, while Digitec specializes in IT and electronics. The company generated sales of 2.7 billion Swiss francs in 2023.

<span class="mw-page-title-main">Swiss Prime Site</span> Swiss property investment company

Swiss Prime Site AG is one of the largest listed real estate companies in Europe. The fair value of the real estate under management is around CHF 26 billion. The portfolio of the company's own real estate has a value of around CHF 13 billion and consists primarily of commercial and retail properties in the most important Swiss metropolitan regions of the Central Plateau. In addition to the real estate investments, the Group companies Swiss Prime Site Solutions and Jelmoli make up the Services segment.

Meyer Burger Technology AG is an industrial manufacturer of solar cells and solar modules, headquartered in Gwatt, a district of Thun, Switzerland. The company's registered shares are listed on the SIX Swiss Exchange.

Leonteq AG is a Swiss company founded in 2007 and headquartered in Zürich. It is specialized in structured financial products and in insurance products in the sector of finance and technology. It is an issuer of its own products, as well as a partner of other finance companies.

<span class="mw-page-title-main">Bank Cler</span>

Bank Cler is a Basel-based Swiss bank founded in 1927. The bank's main area of activity is retail banking for private individuals and small and medium-sized companies. Until it became a wholly owned subsidiary of Basler Kantonalbank in 2019 the bank's shares were listed on the SIX Swiss Exchange.

<span class="mw-page-title-main">Beat Jans</span> Swiss politician (born 1964)

Beat Jans is a Swiss environmental scientist and politician who currently serves as a member of the Federal Council, after being elected in 2023 to succeed Alain Berset, assuming office on 1 January 2024. A member of the Social Democratic Party, he previously served on the National Council from 2010 to 2020, and president of the Executive Council of Basel-Stadt from 2021 to 2023.

<span class="mw-page-title-main">Dadvan Yousuf</span> Kurdish entrepreneur

Dadvan Yousuf is an Iraqi cryptocurrency investor and businessman whose early bitcoin investments made him the youngest self-made billionaire in Switzerland. In November 2021, Yousuf was included in the Forbes 30 Under 30 list. Yousuf and his companies have been the subject of a number of investigations into financial impropriety.

<span class="mw-page-title-main">Fosmanogepix</span> Chemical compound

Fosmanogepix is an experimental antifungal drug being developed by Amplyx Pharmaceuticals It is being investigated for its potential to treat various fungal infections including aspergillosis, candidaemia, and coccidioidomycosis.

<span class="mw-page-title-main">Thomas Matter</span> Swiss businessman, banker, philanthropist and politician

Thomas Matter is a Swiss businessman, banker, philanthropist and politician. He currently serves as a member of the National Council (Switzerland) for the Swiss People's Party since 2014. Matter is estimated to be the second richest politician in the Swiss legislature with an estimated net worth of 150 million Swiss Francs (2017) by Handelszeitung.

<span class="mw-page-title-main">Läckerli Huus</span> Swiss confectionery manufacturer

Läckerli Huus is a Swiss manufacturer of confectionery and baked goods based in Frenkendorf in the canton of Basel-Landschaft.

Alu Menziken Extrusion AG is a Swiss steel manufacturing concern headquartered in Menziken, Switzerland which is specialized in producing semi-finished products and components made from aluminium. Founded 1897 by Alfred Gautschi the group was entirely owned and controlled by the Gautschi family until 2007. Today it is a subsidiary of the Swiss industrial group Montana Tech Components.

HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.

References

  1. ↑ "David Veitch: Chief Executive Officer, Basilea Pharmaceutica AG". Bloomberg . 2023. Retrieved 2024-07-21.
  2. ↑ "Domenico Scala wird Davidoff-Präsident: Vom Fifa-Reformer zum Zigarren-Boss". Blick . 2018-09-12. Retrieved 2024-07-21.
  3. 1 2 3 Full-Year Report 2023, published in Public Now, 12 February 2024, retrieved 12 April 2024.
  4. 1 2 "US pays Basel pharma firm to develop new antibiotic". SWI swissinfo.ch. 2016-04-20. Retrieved 2024-07-20.
  5. 1 2 "Basilea nähert sich der Gewinnzone". Handelszeitung . 27 february 2018.
  6. ↑ "Firmenprofil: Basilea Pharmaceutica International AG, Allschwil". Dun & Bradstreet . 2 January 2024.
  7. ↑ "Basilea Pharmaceutica China Ltd.: Company Profile". Echemi.com. Retrieved 2024-07-20.
  8. ↑ Paul Verbraeken: "Nebenwerte Basilea: Intakte Wachstumsstory". Handelszeitung . 25 May 2019.
  9. ↑ Ruedi Mäder: "Basilea hat einen Partner gefunden: Tochter von GlaxoSmithKline bezahlt über 200 Millionen für Mittel gegen Ekzeme". Basler Zeitung . 13 June 2012.
  10. ↑ Felix Erbacher: "Dollar und mildes Umfeld schüren Erwartungen: Auf die Rapporte von Clariant und Actelion reagieren die Anleger diese Woche erwartungsvoll". Basler Zeitung . 21 february 2015.
  11. 1 2 "Gute Nachricht für Basilea: US-Arzneimittelbehörde gibt positiven Zwischenbefund ab". Basler Zeitung . 4 december 2013.
  12. ↑ "Basilea in neuer Partnerschaft: Vermarktung von neuem Antipilzmittel". Basler Zeitung . 25 february 2010.
  13. ↑ "Vermarktungsrecht in der EU für Mittel gegen Pilzinfektionen". Nordwestschweiz. 24 October 2015.
  14. ↑ "Basilea erhält weitere Meilensteinzahlung von Pfizer". Finanz und Wirtschaft. 2023-11-20. Retrieved 2024-07-20.
  15. 1 2 3 Boyadjian, Rupen (2023-06-06). "Basilea von Ungewissheiten gebremst". Finanz und Wirtschaft. Retrieved 2024-07-20.
  16. ↑ Viola, Axel (2014-06-03). "Nosokomiale Pneumonie: Neues Cephalosporin bessert schneller die Symptomatik". Medscape . Retrieved 2023-01-10.
  17. 1 2 "Basilea antibiotic to treat pneumonia wins European backing". Reuters . Retrieved 2024-07-20.
  18. ↑ "Basilea mit höherem Verlust wegen Kosten für Markteinführung". Basler Zeitung . 2015-02-17. Retrieved 2024-07-20.
  19. 1 2 Romanoff, Soo (2024-04-04). "Basilea Pharmaceutica — Zevtera crosses key US regulatory hurdle". Edison Group. Retrieved 2024-07-21.
  20. ↑ "Finding future medicines". Annual Report: 39. 2023 – via Basilea Pharmaceutica Ltd.
  21. ↑ "Basilea gibt den Umzug des Firmensitzes nach Allschwil, Kanton Basel-Landschaft, für das Jahr 2022 bekannt". boerse.de. 2020-06-30. Retrieved 2024-07-21.
  22. 1 2 "Basilea enters into sale and leaseback agreement for corporate headquarters building". Yahoo! Finance . 2020-06-23. Retrieved 2024-07-20.
  23. ↑ "Bankaktien sind gefragt". Finanz und Wirtschaft. 17 february 2021.
  24. ↑ "Basilea sieht sich auf Kurs, ein führendes Antiinfektiva-Unternehmen zu werden". Finanz und Wirtschaft. 6 january 2024.
  25. ↑ Spieler, Martin (2024-04-15). "Nicht von falschen Dividendenerwartungen blenden lassen". Tages-Anzeiger (in German). Retrieved 2024-07-22.
  26. ↑ "Basilea provides portfolio status update". Yahoo! Finance . 2024-01-05. Retrieved 2024-07-21.
  27. ↑ "FDA Approves New Antibiotic for Three Different Uses". Food and Drug Administration . 2024-04-03. Retrieved 2024-07-22.
  28. ↑ Boyadjian, Rupen (2023-01-24). "Basilea erreicht vorzeitig die Gewinnschwelle". Finanz & Wirtschaft. Retrieved 2024-07-21.
  29. ↑ "GNW-Adhoc: Basilea präsentiert nach erfolgreich implementierter neuer Strategie starke Finanzergebnisse für 2022". Börse online. 2023-02-14. Retrieved 2024-07-21.
  30. ↑ Valentin Handschin: «"Breakeven ist nicht vor 2011 möglich"». Handelszeitung . 23 april 2008.
  31. ↑ "Basilea Pharmaceutica Aktie". boerse.de. 2023. Retrieved 2024-07-21.
  32. ↑ "Besserer Ausblick und mögliche US-Zulassung stützen Basilea-Kurs". Sonntagszeitung . 24 September 2023.
  33. ↑ "Die Antibiotika-Champions aus Allschwil". Basler Zeitung . 15 february 2023.
  34. ↑ "Auf Resistenzen konzentriert". Ärzte-Zeitung . 22 June 2010.
  35. ↑ "Basileas europäischer Zulassungsantrag für Ceftobiprol zur Behandlung von Lungenentzündung zur Prüfung angenommen". Hamburger Abendblatt. 5 October 2012.
  36. ↑ "Basilea nähert sich der Gewinnzone". Handelszeitung . 27 february 2018.
  37. ↑ "Neues Antimykotikum Cresemba: Einführung in Deutschland". Deutsches Ärzteblatt. 2016. Retrieved 2024-07-21.
  38. ↑ "Basilea auf dem Weg zu dauerhaft schwarzen Zahlen Schweiz: Das Biotech-Unternehmen rechnet für 2020 mit weniger Verlust als im Vorjahr. Die liquiden Mittel werden deutlich höher sein als angenommen". Finanz und Wirtschaft. 12 August 2020.
  39. ↑ "Pfizer übernimmt Vertrieb von Cresemba". DAZ Online. 2017-07-21. Retrieved 2024-07-21.
  40. ↑ "Nestlé-Aktie und Co.: Die fünf Schweizer Top-Empfehlungen von Julius Bär". Börse Online. 2018-02-20. Retrieved 2024-07-22.
  41. ↑ "Basilea reports on first Cresemba approval in MENA region". Swiss Biotech Association. 2018-08-13. Retrieved 2024-07-21.
  42. ↑ "Basilea Pharmaceutica to receive first milestone payment on Cresemba sales in Latin America from Knight Therapeutics". Pharmabiz.com. 2024-01-22. Retrieved 2024-07-21.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.